The complex mechanism of BA action in the development of NAFLD/NASH is controlled primarily by the farnesoid X receptor (FXR), activated by primary BAs, and Takeda G protein-coupled receptors 5 (TGR5), activated by secondary BAs [81]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.